These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15516698)

  • 1. Treating diabetic nephropathy--are there only economic issues?
    Mitch WE
    N Engl J Med; 2004 Nov; 351(19):1934-6. PubMed ID: 15516698
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED; Preddie DC
    Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetic nephropathy.
    Goto A
    N Engl J Med; 2002 Sep; 347(12):947-8; author reply 947-8. PubMed ID: 12239270
    [No Abstract]   [Full Text] [Related]  

  • 4. [Threatened diabetic nephropathy. Early administration of ACE inhibitors and AT1 blockers].
    Einecke U
    MMW Fortschr Med; 2002 Apr; 144(15):14. PubMed ID: 12004443
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of the patient with diabetes mellitus and risk of nephropathy: what do we know, and what do we need to learn?
    Hollenberg NK
    Arch Intern Med; 2004 Jan; 164(2):125-30. PubMed ID: 14744834
    [No Abstract]   [Full Text] [Related]  

  • 6. [Considerations on the treatment of incipient diabetic nephropathy (lst of 2 parts)].
    Pérez Blanco FJ; Manzanares L; Moreno G; Cabello MJ
    An Med Interna; 1996 Apr; 13(4):193-7. PubMed ID: 8688481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapy of diabetic nephropathy].
    Barna I
    Orv Hetil; 2003 Jan; 144(4):165-72. PubMed ID: 12621814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of angiotensin receptor blockers in type 2 diabetes, hypertension, and nephropathy.
    Ravera M; Re M; Vettoretti S
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S44-8. PubMed ID: 16565246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
    Bakris GL; Toto RD; McCullough PA
    J Hum Hypertens; 2005 Feb; 19(2):139-44. PubMed ID: 15457206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approach to the treatment of diabetic nephropathy.
    Burke JM
    Pharm Pract Manag Q; 1997 Jul; 17(2):26-35. PubMed ID: 10168175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Revised guidelines for antihypertensive treatment. What is relevant for the general practitioner?].
    Zidek W
    MMW Fortschr Med; 2004 Jan; 146(1-2):37-8. PubMed ID: 18437867
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hypertension in diabetes mellitus. Role of calcium antagonists in its treatment].
    Borrás M; Romero R
    Med Clin (Barc); 1992 Nov; 99(16):620-3. PubMed ID: 1460927
    [No Abstract]   [Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Microalbuminuria as a warning sign of diabetic nephropathy. Test your diabetics early!].
    Dietrich W; Blumenstein M
    MMW Fortschr Med; 2003 Mar; 145(10):40-2. PubMed ID: 12688026
    [No Abstract]   [Full Text] [Related]  

  • 15. [Prevention of microalbuminuria in type 2 diabetes. BENEDICT study].
    Nitschmann S
    Internist (Berl); 2006 Feb; 47(2):199-200; discussion 200. PubMed ID: 16416298
    [No Abstract]   [Full Text] [Related]  

  • 16. Treating hypertension in the diabetic patient: therapeutic goals and the role of calcium channel blockers.
    Caldwell BV
    Clin Ther; 1993; 15(4):618-36; discussion 617. PubMed ID: 8221813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
    Os I; Stenehjem A; Høieggen A; Draganov B; Jenssen T; Holdaas H
    Tidsskr Nor Laegeforen; 2002 Apr; 122(9):918-20. PubMed ID: 12082835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
    Cooper ME
    J Hypertens Suppl; 1996 Dec; 14(6):S11-4. PubMed ID: 9023709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of microalbuminuria in type 2 diabetes: millimeters or milligrams?
    Glassock RJ
    J Am Soc Nephrol; 2006 Dec; 17(12):3276-8. PubMed ID: 17108313
    [No Abstract]   [Full Text] [Related]  

  • 20. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.